42 results about "Spin label" patented technology

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

The methods and compositions disclosed herein concern the synthesis of a novel class of “two-headed” phospholipid-phosphoinositide hybrids possessing a carbon backbone, such as 2,3-diacylthreitol, erythritol or a synthetic module. The second phospholipid head group allows introduction of a biochemical or chemical moiety in a position orthogonal in space to those occupied by the phosphoinositide head group and the two acyl chains. The diacyl moieties allow for the incorporation of Pea-PIP2 into a lipid bilayer, while the Ptdlns(4,5)P2 moiety in the aqueous layer is specifically recognized by lipid binding proteins. In alternative embodiments of the invention, reporters, for example biotin, fluorophores and / or spin labels, are attached to the free amino group of the head groups of such molecules to specifically target the reporters to the lipid-water interface.

A magnetic resonance imaging (MRI) method of obtaining MRI images of a patient and storing the images in physical storage media.

In one aspect, a method for imaging fluid flow and / or perfusion using spin labeling is provided. The method comprises applying a first magnetic gradient sequence at least to a labeling region, applying a first pulsed radio frequency (RF) sequence to the labeling region to label the fluid, the first pulsed RF sequence comprising a first plurality of pulses wherein an amplitude envelope is non-zero, the first plurality of pulses each separated by a respective first plurality of intervals wherein the amplitude envelope is substantially zero, and acquiring at least one first signal emitted from an imaging region a predetermined delay after applying the first pulsed RF sequence.

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

An MRI system and method for imaging perfusion in an arterial spin labeled (ASL) process in which multiplexed echo-planar imaging (M-EPI) is used rather than conventional EPI, to thereby speed up imaging and generate sets of images that show different phases of perfusion and provide additional benefits. A single multiband RF excitation pulse can be used to excite multiple slices for imaging, or a time sequence of multiband pulses can be used to further increase the number of slices.

The present invention relates to a kinase labelled at an amino acid naturally present or introduced in the P-loop of said kinase, wherein said labelling is effected at a free thiol or amino group of said amino acid and said label is (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitors, a method of determining the kinetics of ligand binding and / or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.

A system and method is provided for magnetic resonance angiography (MRA) that includes applying a first labeling pulse sequence to a first labeling region having a first portion of a vasculature of a subject extending through the first labeling region to label spins moving within the first labeling region. A second labeling pulse sequence is applied to a second labeling region having a second portion of a vasculature of the subject extending through the second labeling region to label spins moving within the second labeling region. The first and second labeling pulse sequences include different labeling techniques. An imaging pulse sequence is applied to an imaging region having a third portion of a vasculature of the subject extending through the imaging region that is displaced from the first and second labeling region to acquire imaging data from the spins labeled by the first labeling pulse sequence and the second labeling pulse sequence. An MRA image is reconstructed of at least the third portion of the vasculature of the subject from the medical imaging data.

The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants.

The invention discloses a magnetic resonance artery spin labeling cerebral perfusion imaging data artifact graph removal method. The method comprises steps that a structure image of a detected brain is acquired, the structure image is segmented to generate a grey matter probability graph GM and a white matter probability graph WM, the grey matter probability graph GM and the white matter probability graph WM form a reference image pmCBF, and artifact graphs of rheoencephalograms CBF1-CBFn at n time points of the detected brain are removed by utilizing the reference image pmCBF. The method is advantaged in that the artifact graphs of the rheoencephalogram sequence can be effectively removed, error reduction is realized, and image quality is improved.

This invention pertains to the discovery that certain endohedral fullerenes are functional paramagnetic materials exhibiting increased relaxation times. These endohedral fullerenes provide improved labels for use in electron spin resonance (ESR) detection systems.

Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the prevention and treatment of fibrocystic disease of breast, premenstrual dysphoric syndrome and associated symptomology, prevention and treatment of migraine headache, cyclic vomiting syndrome, rectal hemorrhoids, trigeminal neuralgia, peripheral vascular disease, influenza, peridontitis and gingivitis, herpes zoster, herpes simplex, and post-herpetic neuralgia.

A system and method is provided for magnetic resonance angiography (MRA) that includes applying a labeling pulse sequence to a labeling region of a subject having a first portion of a vasculature extending through the labeling region to label spins moving within the labeling region and acquiring labeling data from labeled spins moving in the subject. The labeling data is analyzed to determine a velocity of the labeled spins and the velocity of the labeled spins is compared to a predetermined metric to determine when the subject is in a predetermined cardiac phase. When in a desired cardiac phase, an imaging pulse sequence is applied to an imaging region of the subject having a second portion of the vasculature extending through the imaging region to acquire medical imaging data from the imaging region. The imaging region is separate from labeling region.

Spin labeled ice binding compounds (IBCs) including ice binding proteins (IBPs), also called antifreeze proteins (AFPs) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin labeled IBCs include: (1) ability to cryo-protect biological samples; (2) the relative positions and orientations of the spin labeling groups in an IBC may also be cryo-preserved; (3) positions and orientations of spin labeling groups to an IBC can be selected with great freedom and without technical barrier to making multiple spin labels in an IBC; and (4) water solubilities of spin labeled IBCs are potentially high, enabling use of a solvent that is primarily water for DNP at low temperatures.

The present invention relates to a kinase labeled at an amino acid having a free thiol or amino group, wherein said amino acid is naturally present or introduced in the activation loop of said kinase, with (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitor, a method of determining the kinetics of ligand binding and / or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.

The invention relates to a labeling reactant of formula (I) useful for labeling an oligonucleotide wherein: R is a temporary protecting group. A is either a phosphorylating moiety or a solid support tethered to Z via a linker arm E''. Z is a bridge point and is formed from E is a linker arm between R and Z. E' is a linker arm between Z and Z'. E'' is a linker arm between Z and A. E''' is a linker arm between Z' and G. Z' is a purine or pyrimidine base. G is a protected bivalent aromatic structure, tethered to two iminodiacetic acid ester groups N(CH2COOR'')2, or G is a structure selected from the group consisting of or G is a protected functional group, or G is a protected or unprotected organic dye, hapten or a spin label.

The invention belongs to the field of molecular biology, and relates to application of previous 50 amino acids of Bacillus subtilis l68 flagellin Hag, and a novel method for improving the expression quantity of foreign proteins in Bacillus subtilis, and in particular relates to a method for improving the expression quantity of foreign proteins by way of fusion expression. A fusion label Hag 50 coding sequence is fused and recombined with that of the foreign proteins to construct a recombinant plasmid in fusion expression and convert the Bacillus subtilis. The obtained recombinant bacteria have already improved the expression quantity of foreign proteins successfully.

Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the treatment of dense breasts.

The invention belongs to the technical field of molecular biology, and provides application of fusion label to promotion of Kuma030 protease soluble expression and non-affinity chromatography fast purification. The fusion expression strategy is combined with the self property of the Kuma030 protease; a method of promoting the soluble expression of Kuma030 protease in colibacillus and purificationby the fusion label is obtained. The method can be used for promoting the high expression of the protease; in addition, the pure protein after the fusion expression label removal can also be obtained;the purity is high; meanwhile, the advantages of simplicity, convenience and low energy consumption are realized; the method is more suitable for large-scale industrial application.

The invention discloses a spin labeled fluorescent probe with single electron structure. The spin labeled fluorescent probe with single electron structure is prepared by the following method: (1) adding rhodamine B and 4-hydroxy-2, 2, 6, 6,-tetramethyl-piperidine nitrogen oxygen free radical into a reaction solvent dichloromethane, adding 4-dimethylaminopyridine to carry out reaction for 20min, then adding N, N'-dicyclohexyl carbodiimide, carrying out reaction at room temperature under argon protection for 24h; and (2) at the end of the reaction, removing the solvent, and subjecting the remaining materials to column chromatography separation: adopting dichloromethane / methanol=20 / 1 (v / v) as the eluant, taking 200-mesh neutral alumina as the stationary phase, collecting eluent, and removing the eluate. The spin labeled fluorescent probe with single electron structure provided by the invention has good cell permeability and low cytotoxicity, can be used for detection of intracellular hydroxyl radicals, mercapto free radicals and, cellular redox environment and oxidation resistance evaluation research of polyphenolic antioxidants.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds

The invention relates to a method of MR imaging of at least a portion of a body (10) placed in a main magnetic field within the examination volume of a MR device (1). It is an object of the invention to facilitate the planning of an arterial spin labeling (ASL) MR imaging session and to improve the image quality in perfusion weighted MR imaging. The method of the invention comprises the following steps: acquiring angiographic MR signal data by subjecting the portion of the examined body (10) to one or more MR angiography scans; deriving quantitative blood flow parameters from the angiographic MR signal data;—computing a labeling efficiency of an ASL sequence from the sequence parameters of the ASL sequence and from the quantitative blood flow parameters; optimizing the sequence parameters by maximizing the labeling efficiency; acquiring perfusion weighted MR signal data by subjecting the portion of the body to the ASL sequence; and—reconstructing a MR image from the perfusion weighted MR signal data. Moreover, the invention relates to a MR device (1) and to a computer program for a MR device (1).

The invention discloses a spin-labeling rotenone oxime ester compound, its preparation method and application. The structural formula of the spin-labeling rotenone oxime ester compound is as show in the formula, wherein the substituent R can be 2,2,5,5-tetramethyl pyrroline nitronyl nitroxide radical, or 2,2,5,5-tetramethyl tetralin pyrroline nitronyl nitroxide radical, or -2,2,6,6-tetramethyl-tetralin pyridine nitronyl nitroxide radical or 2,2,6,6-tetramethyl-piperidine nitronyl nitroxide radical. The spin-labeling rotenone oxime ester compound provided by the invention can be applied in the preparation of antitumor drugs.

Spin labeled ice binding compounds (IBCs) including ice binding proteins (IBPs), also called antifreeze proteins (AFPs) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin labeled IBCs include: (1) ability to cryo-protect biological samples; (2) the relative positions and orientations of the spin labeling groups in an IBC may also be cryo-preserved; (3) positions and orientations of spin labeling groups to an IBC can be selected with great freedom and without technical barrier to making multiple spin labels in an IBC; and (4) water solubilities of spin labeled IBCs are potentially high, enabling use of a solvent that is primarily water for DNP at low temperatures.

The invention discloses a spin-labeling rotenone oxime ester compound, its preparation method and application. The structural formula of the spin-labeling rotenone oxime ester compound is as show in the formula, wherein the substituent R can be 2,2,5,5-tetramethyl pyrroline nitronyl nitroxide radical, or 2,2,5,5-tetramethyl tetralin pyrroline nitronyl nitroxide radical, or -2,2,6,6-tetramethyl-tetralin pyridine nitronyl nitroxide radical or 2,2,6,6-tetramethyl-piperidine nitronyl nitroxide radical. The spin-labeling rotenone oxime ester compound provided by the invention can be applied in the preparation of antitumor drugs.